Engineering High-Speed Pen Injector Final Assembly Machine: Solving the Cartridge Press-Fit Challenge

Editor’s Note: This article has been updated by the author on October 19, 2026 for clarification.

In the life cycle of a pen injector, final assembly is where the stakes are highest. Unlike preassembly, where ejected units consist only of low-cost injection-molded plastic components, a failure at the final assembly stage means losing a prefilled drug cartridge worth several dollars. For glucagon-like peptide-1 receptor agonists, insulin biosimilars, and other high-value biologics, that figure can climb significantly higher. When a final assembly line operates at speeds of 160 pens per minute (ppm), even a modest reject rate of 1% translates into substantial financial loss and wasted API over a production shift.^1,2

This economic reality demands a fundamentally different engineering philosophy for pen injector final assembly. Speed alone is not the objective; first-pass yield is the ultimate metric of success. Every design decision, from machine architecture and servo control to sensor selection and data architecture, must be evaluated against a single question: Does this reduce the probability of rejecting a unit that contains a live drug cartridge?

This article examines the engineering principles behind high-speed pen injector final assembly systems, with particular focus on the cartridge press-fit operation, which represents the single most crucial and most failure-prone step in the entire process. By exploring modular architecture, real-time force-displacement monitoring, multipoint dimensional verification, and stringent data integrity protocols, this article examines engineering requirements aimed at an assembly qualification rate of 99.5% or greater in commercial-scale production.^1,2

Why Final Assembly Is the Highest-Risk Stage

A pen injector final assembly line receives 2 categories of input: the preassembled pen mechanism (comprising the housing, dosing engine, and drive sleeve) and the prefilled drug cartridge (typically a 3-mL glass or polymer barrel). The primary function of the line is to marry these 2 elements, verify functional performance, and produce a finished device ready for labeling and secondary packaging.

The risk profile of this operation is inherently asymmetric. A preassembled pen mechanism rejected at an earlier stage costs only a fraction of a dollar. However, the moment a drug cartridge is introduced into the assembly sequence, the cost of rejection multiplies by an order of magnitude. The cartridge contains a filled and stoppered barrel, a crimped aluminum cap, and a precisely measured volume of API. None of these components can be recovered or reworked once the cartridge enters the press-fit station.^1,2

This asymmetry shapes every aspect of final assembly engineering. The line must be designed not merely to assemble quickly, but to assemble correctly on the first attempt, every time. The tolerance for process variation is effectively zero. Furthermore, the handling of the cartridge must be gentle enough to prevent cosmetic damage to the aluminum cap or particulate generation from the rubber stopper, while maintaining the rigid positional control required for high-speed automation.³

Modular Architecture: Building Around the Critical Node

Conventional assembly line design often distributes stations linearly, treating each operation as roughly equivalent in importance. For pen injector final assembly, this approach is inadequate. The cartridge press-fit operation is not simply one station among many; it is the critical node around which the entire system must be architected.

A modular multicell architecture addresses this requirement effectively. Rather than a single monolithic line, the system is organized into discrete functional cells, each optimized for a specific phase of the assembly process.²

The 2-Cell Approach

The platform uses 24 stations arranged in 2 primary cells. Nominal throughput depends on the configuration: the version described in reference 2 has an output of 84 ppm, while higher-throughput configurations are available up to 160 ppm²:

• Cell 1: mechanism preparation and component loading. This cell handles the feeding, orientation, and inspection of the incoming preassembled pen bodies and drug cartridges. Crucially, it must use zero-contact or low-friction feeding mechanisms (such as specialized conveyor systems rather than traditional vibratory bowls) to prevent thermal excursions or particulate generation that could compromise the biologic drug product.
• Cell 2: cartridge integration, press-fit, and verification.This cell handles prefilled cartridge loading, final winding, force-displacement-monitored pressing, final assembly, vision inspection, and reject handling.²

This modularity offers several distinct engineering advantages. First, it allows the press-fit cell to operate with tighter environmental controls and more sophisticated instrumentation than would be practical across an entire line. Second, it enables independent installation qualification and operational qualification of each cell, simplifying the overall good manufacturing practice (GMP) documentation burden and accelerating the factory acceptance test schedule. Third, it provides a natural framework for scaling; additional cells can be integrated to increase throughput without redesigning the core system architecture.²

The Cartridge Press-Fit: Engineering for Zero Defects

The cartridge press-fit operation is deceptively simple in concept: insert a glass or polymer cartridge into the pen housing until it seats firmly against a mechanical stop. In practice, this operation concentrates nearly all of the critical failure modes in final assembly.^3,4

The cartridge is a fragile, high-value component. Excessive force during insertion can induce microcracks in the glass barrel. These defects may not be visible to standard optical inspection systems but can propagate under storage conditions or during patient use, leading to leakage, loss of sterility, or complete device failure. Conversely, insufficient force results in an incompletely seated cartridge, which compromises dose accuracy and may cause mechanical jamming during injection.^3,4

The engineering challenge is compounded by inherent material variability. Glass cartridges exhibit dimensional tolerances that, although within International Organization for Standardization (ISO) specifications, create measurable variation in insertion-force requirements from unit to unit. Rubber stoppers and aluminum crimp caps introduce additional friction variables. The press-fit system must accommodate this natural variation while maintaining absolute control over the force applied to each individual unit.

Real-Time Force-Displacement Curve Monitoring

The solution to the press-fit challenge lies in continuously monitoring the force-displacement curve throughout the entire insertion stroke. Rather than relying on simple peak-force thresholds, which cannot distinguish between a properly seated cartridge and one that has encountered an obstruction midway through the stroke, the system captures the complete force profile as a function of displacement.

Each press-fit operation generates a characteristic curve. A properly executed insertion produces a predictable force signature: initial contact, progressive resistance as the cartridge engages the housing bore, and a defined force peak at final seating. Deviations from this expected profile, such as an unexpected force spike indicating excessive interference or another abnormal pressing condition.

For a system configured to operate at 160 ppm, the system requires high-resolution piezoelectric force sensors paired with precision servo motors. These sensors provide the measurement bandwidth necessary to capture transient force events that occur on millisecond timescales. The press-fit operation completes in well under 1 second; only sensors with sufficient dynamic response can reliably detect brief force anomalies associated with abnormal pressing conditions.²

The acceptable force-displacement envelope is established during process validation and locked under electronic change control. Any modification to the envelope parameters requires formal change control, including an impact assessment and appropriate verification or requalification to ensure that the validated process cannot be inadvertently altered during production runs.²

Multipoint Dimensional Verification for Dose Accuracy

Force monitoring alone, although necessary to prevent damage, is not sufficient to guarantee dose accuracy in the finished device. The functional performance of a pen injector depends on precise geometric relationships between the cartridge, the dosing mechanism, and the drive components. Even microscopic deviations in cartridge seating depth can alter the effective stroke length of the plunger rod, directly affecting the delivered dose volume.

Linear variable differential transformers (LVDTs) provide the measurement precision required for postassembly dimensional verification. These sensors offer micron-level resolution and excellent long-term stability, characteristics that make them superior to optical sensors for in-line pharmaceutical applications in which measurement drift is unacceptable.²

A robust multipoint LVDT verification strategy measures critical dimensions at several locations on the assembled device:

• Plunger rod protrusion: Verifying the exact position of the plunger rod relative to the pen body.
• Cartridge seating depth:Confirming the cartridge is fully seated against the internal mechanical stops.
• Final rod position and rod-to-cartridge-plug gap:Verifying the final rod position and the critical gap to the cartridge plug.²

Each measurement is verified against validated acceptance criteria. Units outside the specified dimensional envelope are flagged for rejection before transfer to subsequent inspection or downstream operations.

The combination of force-displacement monitoring during assembly and LVDT dimensional verification after assembly creates a layered quality assurance strategy. The first layer prevents damage; the second confirms correct geometry. Together, these controls support dimensional conformance; dose accuracy must be demonstrated through the appropriate device performance tests.²

Unit-Level Traceability and 21 CFR Part 11 Compliance

At a nominal line speed of 160 ppm, the theoretical 24-hour output is 230,400 units, before allowance for downtime, changeovers, or rejects. Where electronic records are required or relied on for regulated activities, applicable controls under 21 CFR Part 11 and EU GMP Annex 11 support record attribution, security, and retrievability for the required retention period.^5,6

Radiofrequency identification-based pallet identification systems provide the foundation for unit-level traceability. Each transport pallet or nest position carries a unique identifier that links the physical unit to its complete digital process record. As the unit progresses through each station, process parameters, force curves, dimensional measurements, test results, timestamps, and operator actions are automatically associated with that identifier in the supervisory control and data acquisition (SCADA) system.

Because carriers are reused, pallet and nest identifiers must be associated with the relevant batch and loading event so that records from successive units are not conflated.

This approach supports investigation of unit-level assembly history and helps control risks of missing or misassociated records. If a quality investigation requires examination of a specific unit’s assembly history, the complete record can be retrieved without ambiguity. The system maintains a continuous, auditable chain of custody from cartridge insertion through final packaging.^5,6

Electronic records are protected by stringent role-based access controls, comprehensive audit trails that capture all data modifications, and automated backup procedures. The control system architecture ensures that process data cannot be altered or deleted without generating a permanent, traceable record of the change, a fundamental requirement for pharmaceutical manufacturing systems.^5-7

Managing Utility Interruptions: The Conservative Approach

An aspect of final assembly system design that is often overlooked is the response to utility interruptions, power failures, compressed air loss, or emergency stops. In a system in which each unit in process contains a high-value drug cartridge, the consequences of an uncontrolled shutdown extend beyond simple production loss.

The engineering principle for managing utility interruptions in final assembly is straightforward but highly conservative: Upon any utility failure, all units currently within the active assembly system are automatically classified as rejected.

No attempt is made to determine which units may have been unaffected by the sudden loss of air pressure or servo control. The economic cost of scrapping several dozen in-process units is trivial compared with the regulatory and patient-safety risks of releasing a potentially compromised device.

To protect the data associated with these events, uninterruptible power supply (UPS) systems are integrated into the control architecture. The UPS protects data integrity during power events, ensuring that batch records and audit trails are properly closed and saved before the programmable logic controller and SCADA systems shut down. Upon power restoration, the system executes a controlled restart sequence that requires operators to clear all in-process material before resuming normal production.

This conservative approach reflects a broader design philosophy: In pharmaceutical final assembly, the cost of a false acceptance always exceeds the cost of a false rejection.

Achieving First-Pass Yields

High-speed pen injector final assembly is not simply a faster version of manual assembly. It is a distinct engineering discipline that requires purpose-built architecture, advanced process monitoring, and rigorous data management, all designed around the central reality that every rejected unit carries the cost of a lost drug cartridge.

The convergence of real-time force-displacement monitoring, multipoint LVDT dimensional verification, and unit-level digital traceability enables modern assembly systems to achieve the first-pass yields that pharmaceutical economics demand. The ability to deploy these systems and qualify them efficiently is important for meeting production demand without compromising quality or profitability.²

The engineering challenge of the cartridge press-fit is substantial, but it is solvable provided the system is designed from the outset with the understanding that in final assembly, precision is not a luxury. It is the minimum requirement for success.

References

1. Xu J. The complete technical guide to injection pen assembly lines: pre-assembly, final assembly, functional testing, and GMP validation. Drofen. July 1, 2026. Accessed July 14, 2026. https://www.drofen-pharma.com/info/the-complete-technical-guide-to-injection-pen-103559400.html
2. Xu J. Complete engineering guide: selecting and implementing high-speed pen injector final assembly systems. Drofen. June 16, 2026. Accessed July 14, 2026. https://www.drofen-pharma.com/info/injector-final-assembly-machine-103542062.html
3. Needle-Based Injection Systems for Medical Use—Requirements and Test Methods—Part 1: Needle-Based Injection Systems. ISO 11608-1:2022. International Organization for Standardization; 2022.
4. US Food and Drug Administration. Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products: Guidance for Industry and FDA Staff. June 2013.
5. Electronic Records; Electronic Signatures, 21 CFR pt 11.
6. European Commission. EudraLex Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Annex 11: Computerised Systems. European Commission; 2011.
7. International Society for Pharmaceutical Engineering. GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems. International Society for Pharmaceutical Engineering; 2022.

About the Author

Jordan Xu is managing director at Drofen Machinery Equipment Co, Ltd, a turnkey system supplier of automated assembly lines for injection pens and prefilled syringes for global pharmaceutical manufacturers and contract development and manufacturing organizations.